Every material Form 8-K CHAMPIONS ONCOLOGY, INC. has filed with the SEC since March 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Champions Oncology reported unaudited first-quarter fiscal 2027 results for the period ended July 31, 2026, with revenue of $15.2 million, up 8.8% from a year earlier. The net loss narrowed to $426,000 from $466,000, and adjusted EBITDA rose to $671,000 from $59,000, though the company still reported a loss and spent more on sales and marketing.
Oncology revenue of $15.2 million, up from $14.0 million in the prior-year quarter
Net loss of $426,000 versus $466,000 a year earlier; basic loss per share of $0.03 in both periods
Adjusted EBITDA of $671,000 versus $59,000; oncology services margin of 51% versus 43%
Sales and marketing expense rose 66.6% to $3.1 million; cash used in operations was $492,000 and cash ended the quarter at $4.4 million with no debt
Champions Oncology reported record fiscal 2026 revenue of $59.4 million, up 4% from $56.9 million, for the year ended April 30, 2026. The company swung to a net loss of $1.2 million, compared with net income of $4.7 million a year earlier, as operating costs rose and the prior year's $4.5 million data license revenue did not recur.
Fiscal 2026 oncology revenue was $59.4 million, up 4% from $56.9 million; the prior year included about $4.5 million of data license revenue that did not recur.
Net loss was $1.2 million for fiscal 2026 versus net income of $4.7 million in fiscal 2025; adjusted EBITDA was $1.6 million versus $7.1 million.
Fourth quarter revenue was $13.8 million, up 12% from $12.4 million, and the quarterly net loss narrowed to $667,000 from $1.8 million.
Cash was $4.9 million at April 30, 2026, with no debt, down from $9.8 million a year earlier.
Champions Oncology board accepted the resignation of director Dr. Philip Breitfeld on March 24, 2026, and appointed Dr. Brian Alexander to fill the vacancy. The company said the resignation was not due to any disagreement over its operations, policies, or practices.
Board accepted Dr. Philip Breitfeld's resignation as a director on March 24, 2026
Dr. Brian Alexander appointed director to fill the resulting vacancy
Alexander is CEO of Valo Health and CEO-Partner at Flagship Pioneering, both since November 2024
Filing states no related party transactions reportable under Item 404(a) for Alexander
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CHAMPIONS ONCOLOGY, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →